Zura Bio (ZURA) to Release Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Zura Bio to post earnings of ($0.17) per share for the quarter.

Zura Bio Trading Down 2.9 %

Shares of NASDAQ:ZURA opened at $1.35 on Tuesday. Zura Bio has a 12 month low of $1.07 and a 12 month high of $6.35. The company’s fifty day moving average price is $1.50 and its 200 day moving average price is $2.78.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research note on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zura Bio stock. Bank of America Corp DE increased its stake in shares of Zura Bio Limited (NASDAQ:ZURA) by 31.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,222 shares of the company’s stock after buying an additional 9,966 shares during the quarter. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 at the end of the most recent quarter. 61.14% of the stock is owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.